2021-01-03,b'RT @contrarianvue: @gamechangercap Forgot $ARVN as well. $CCCC is interesting. I watched the recent virtual call on $NRIX and also liked wh\xe2\x80\xa6'
2021-01-03,b'RT @contrarianvue: @gamechangercap BTK is a validated target. $PRNB recently taken out. Not much in the space as a pure play other than $KY\xe2\x80\xa6'
2021-01-02,b'RT @contrarianvue: @gamechangercap BTK is a validated target. $PRNB recently taken out. Not much in the space as a pure play other than $KY\xe2\x80\xa6'
2021-01-02,b'RT @gamechangercap: @contrarianvue Yeah I liked what the $NRIX CEO had to say on a recent call. I have owned $CCCC for awhile they do mono\xe2\x80\xa6'
2021-01-02,b'RT @contrarianvue: @gamechangercap Forgot $ARVN as well. $CCCC is interesting. I watched the recent virtual call on $NRIX and also liked wh\xe2\x80\xa6'
2021-01-02,b'@gamechangercap Forgot $ARVN as well. $CCCC is interesting. I watched the recent virtual call on $NRIX and also liked what they had to say. \n\nI\xe2\x80\x99m also going to get long $ASND next week.'
2021-01-02,"b""@contrarianvue Yeah I liked what the $NRIX CEO had to say on a recent call. I have owned $CCCC for awhile they do mono and bi dac which differentiates them. Also $BYSI which isn't a pure play but undervalued I believe."""
2021-01-02,b'@gamechangercap BTK is a validated target. $PRNB recently taken out. Not much in the space as a pure play other than $KYMR $NRIX $CCCC. Would love to hear counter argument if you have one though. cheers'
2021-01-01,"b""January portfolio update (by position size): \n\n$NVCR \n$NET\n$ZLAB\n$BTC\n$PSNL\n$TMDX\n$FLGT\n$SILK\n$CCCC\n$BYSI\n$SWAV\n$GWPH\n$FREQ\n$PROF\n$AYX\n$ETH\n\nOptions: $NVCR Jan \xe2\x80\x9822 $115 calls &amp; mar \xe2\x80\x9821 $145 calls \n\n$SH Feb '21 $20 calls , $SQQQ Mar '21 $20 calls, $BIS Jan '21 $26 calls"""
2020-12-31,"b'REVERSALtoDOWN: $CCCC C4 Therapeutics, Inc. https://t.co/kRQmDYc8Oq \xf0\x9f\x93\x89 \xf0\x9f\x94\x9c TradeIdeas via \xe2\x9f\xb6 https://t.co/ZgCyz4rX3x'"
2020-12-29,b'RT @MarcJacksonLA: $CCCC - C4 Therapeutics: Preclinical Stage Protein Degrader Developer With A Differentiated Approach. https://t.co/C4JW6\xe2\x80\xa6'
2020-12-28,b'RT @WayoftheMaster7: $QS $ADBE $MAS $TTCF $KNTE $BEAM $EH $CMBM $HELE $CLSK $QLD $AXSM $IPOD $HRTX $YEXT $LOVE $CCCC..... #TheStrat https:/\xe2\x80\xa6'
2020-12-28,"b""RT @WayoftheMaster7: Hit em if you want em! #TheStrat \n\nInside D Add's... $ALLK $ENPH $BEAM $CCCC $RUN $WMG $CSII $BE $BRBR $AOSL $SWBI $YE\xe2\x80\xa6"""
2020-12-28,"b""RT @WayoftheMaster7: Hit em if you want em! #TheStrat \n\nInside D Add's... $MAXR $BURL $PRVB $EGHT $FLS $CDNA $ALL $ALRM $TX $TBIO\n\n3-1 D...\xe2\x80\xa6"""
2020-12-28,b'RT @jaywhitcraft: Favorites \xe2\x80\x93 $AMZN $ARCT $ASAN $ATOM $CCCC $COUP $CRLBF $CRSR $CVAC $DBX $DOCU $EXAS $FLGT $FSLY $FUBO $FUV $HOLX $INSG $I\xe2\x80\xa6'
2020-12-27,b'RT @cpcien: @gamechangercap What brought you to $cccc out of the degredation group?'
2020-12-27,b'Favorites \xe2\x80\x93 $AMZN $ARCT $ASAN $ATOM $CCCC $COUP $CRLBF $CRSR $CVAC $DBX $DOCU $EXAS $FLGT $FSLY $FUBO $FUV $HOLX $INSG $IPOC $ISRG $LAC $LASR $MRVI $MWK $NIO $NK $NNOX $NVAX $ONCT $PDD $PLTR $PRPL $QDEL $QTRX $RUN $SHOP $STAA $SUPN $TDOC $TXG $UBER $VERI $VFF $VIPS $VVPR'
2020-12-27,b'@gamechangercap What brought you to $cccc out of the degredation group?'
2020-12-27,"b'My top investment ideas for 2021. I own all of these currently. Major themes Edge networks, medtech, and crypto \n\n$NET\n$NVCR\n$TMDX \n$SWAV / $SILK\n$PROF\n$ETH / $BTC\n$CCCC'"
2020-12-27,b'$CCCC - C4 Therapeutics: Preclinical Stage Protein Degrader Developer With A Differentiated Approach. https://t.co/C4JW656LzR  https://t.co/xJjrAVtaPt'
2020-12-27,b'$CCCC - C4 Therapeutics: Preclinical Stage Protein Degrader Developer With A Differentiated Approach. https://t.co/zIUTMiTfeY #finance #stockmarket #markets'
2021-01-07,b'$CCCC C4 Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference https://t.co/l2XMuMRpRO'
2021-01-07,b'$CCCC NEW ARTICLE : C4 Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference https://t.co/y5ctyV9jJq https://t.co/fmLU2sTipS'
2021-01-07,"b'$CCCC [15s. delayed]: Issued Press Release on January 07, 07:00:00: C4 Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference https://t.co/V4J7InVPoh'"
2021-01-07,b'$CCCC C4 Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference\nhttps://t.co/Rmv6vA1VZQ'
2021-01-07,b'C4 Therapeutics Announces Key 2021 Milestones to Support Progress Toward Goal of Four Clinical-Stage Programs by Year-End 2022 $CCCC https://t.co/hWgIeYHxEO'
2021-01-06,"b'A Form 8-K [Press/News Current Report] filing has been made with the SEC:  $CCCC #C4Therapeutics, Inc  https://t.co/S8hqam4PZH'"
2021-01-06,b'$CCCC / Cache Capital files form 8-K - Regulation FD Disclosure -  8-K https://t.co/iHlRRDAPIE'
2021-01-06,b'C4 Therapeutics to deliver four programs into the clinic by the end of 2022 $CCCC https://t.co/NjY07Pp0ey'
2021-01-06,b'C4 Therapeutics to deliver four programs into the clinic by the end of 2022 $CCCC https://t.co/FYMVs5F6hO'
2021-01-06,b'$CCCC - C4 Therapeutics to deliver four programs into the clinic by the end of 2022 https://t.co/R0n6RJEHK9'
2021-01-06,"b""Rose Above Previous Day's High today: $PSTH $RMR $SCX $CAAP $AGEN $PTIN $RJI $SHI $ED $TCPC $CBFV $CLDR $NXRT $GSG $DBE $EGIS $ZDGE $MPLX $CCB $CCCC ... https://t.co/TBYRpvrFqi"""
2021-01-06,b'ISR Stock: Why Little-Known Isoray Is Surging 200% Today\n\n$ISR $CCCC  \n\nhttps://t.co/mCq1ruYphF'
2021-01-06,b'$CCCC C4 Therapeutics Announces Key 2021 Milestones to Support Progress Toward Goal of Four Clinical-Stage Programs by Year-End 2022 https://t.co/uPtSDk3icj'
2021-01-06,b'ISR Stock: Why Little-Known Isoray Is Surging 200% Today $ISR $CCCC https://t.co/KO8zjaqkyj'
2021-01-06,b'RT @TheStockWire: $CCCC\nC4 Therapeutics Announces Key 2021 Milestones to Support Progress Toward Goal of Four Clinical-Stage Programs by Ye\xe2\x80\xa6'
2021-01-06,b'$CCCC - C4 Therapeutics Announces Key 2021 Milestones to Support Progress Toward Goal of Four Clinical-Stage Programs by Year-End 2022 https://t.co/yO0XPnKzYh https://t.co/uRc8tj5Lgr'
2021-01-06,b'C4 Therapeutics expects to initiate Phase 1/2 trial of CFT7455 in 1H21\n$CCCC'
2021-01-06,b'$CCCC NEW ARTICLE : C4 Therapeutics Announces Key 2021 Milestones to Support Progress Toward Goal of Four Clinical-Stage Programs by Year-End 2022 https://t.co/36bnUra0le https://t.co/umTAjaHJ7M'
2021-01-06,"b'$CCCC [15s. delayed]: Issued Press Release on January 06, 07:00:00: C4 Therapeutics Announces Key 2021 Milestones to Support Progress Toward Goal of Four Clinical-Stage Programs by Year-End 2022 https://t.co/IRFF7Pfbgl'"
2021-01-06,b'$CCCC\nC4 Therapeutics Announces Key 2021 Milestones to Support Progress Toward Goal of Four Clinical-Stage Programs by Year-End 2022'
2021-01-06,b'$CCCC C4 Therapeutics Announces Key 2021 Milestones to Support Progress Toward Goal of Four Clinical-Stage Programs by Year-End 2022\nhttps://t.co/saSV555HSk'
